Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...

FILE: Gilead Sciences logo displayed on a laptop screen and medical pills are seen in this illustration photo taken in Krakow, Poland on 18 October 2021. Picture: Jakub Porzycki / NurPhoto ...

This transformation, marked by a fresh logo and modernized brand identity ... of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 Gilead Sciences, Inc. and Merck , known as ...

That brand is more than just a logo - it’s your company’s reputation ... including a recent campaign from Gilead Science. Meanwhile, Kantar recorded a 208% jump in spending on podcast pharma ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...